Regeneron Pharmaceuticals
$734.81Change from previous close: −3.09%Absolute change: −$23.46
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 14,343 | 14,202 | 13,117 | 12,173 | 16,072 |
| Cost of revenue | 7,951 | 7,103 | 6,255 | 5,153 | 5,298 |
| Gross profit | 6,392 | 7,100 | 6,862 | 7,020 | 10,774 |
| Selling, general and administrative | 2,700 | 2,954 | 2,631 | 2,116 | 1,825 |
| Research and development | 5,850 | 5,233 | 4,625 | 3,848 | — |
| Operating income | 3,702 | 4,145 | 4,233 | 4,994 | 8,995 |
| EBIT | 3,702 | 4,145 | 4,233 | 4,994 | 8,995 |
| EBITDA | 4,246 | 4,628 | 4,654 | 5,335 | 9,281 |
| Interest expense | 43.8 | 55.2 | 73.0 | 59.4 | 57.3 |
| Pre-tax income | 5,231 | 4,780 | 4,199 | 4,859 | 9,326 |
| Income tax | 726 | 367 | 246 | 520 | 1,251 |
| Net income | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 |
| Net income to common shareholders | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 |
| Basic EPS | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 |
| Diluted EPS | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 |
| Average shares (basic) | 105 | 108 | 107 | 107 | 106 |
| Average shares (diluted) | 109 | 115 | 114 | 114 | 112 |
| Dividend per share | 3.52 | — | — | — | — |